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Introduction
Recent literature has focused on the potential for
platelet rich plasma (PRP) products to provide relief
for various musculoskeletal diseases, conditions, and
disorders1. PRP refers to blood solutions with platelet
concentrations above baseline values1. Current evi-
dence suggests that platelets contribute many func-
tions in antimicrobial host defense, including their
ability to release potent antimicrobial peptides from
their alpha granules2,3. These peptides have been
shown to possess broad-spectrum antimicrobial activ-
ity against gram negative gram positive, and fungal
pathogens4,5.
In addition, PRP products have demonstrated an in
vitro antibacterial effect against gram negative (Es-
cherichia coli 6,7, Klebsiella pneumoniae 8, and Pro-
teus mirabilis7) and gram positive bacteria (Staphylo-
coccus aureus 6,9, Bacillus megaterium7, and Entero-
coccus faecalis7). Other studies have found no in vit-
ro activity against gram negative (Enterobacter cloa-
cae8) and gram positive bacteria (Enterococcus fae-
calis6, Bacillus subtilis8, Bacillus cereus8, and Staphy-
lococcus epidermidis8). Mixed results have been
shown with Pseudomonas aeruginosa6,7. In fact, Bi-
elecki et al. demonstrated that platelet-rich gel may
actually induce the in vitro growth of P. aeruginosa6.
Tang et al.10 were the first to suggest a direct rela-
tionship between platelet concentration and antimi-
crobial effects. While no studies have directly com-
pared PRP antimicrobial activity to pharmaceuticals,
one study did find similar inhibition as has been seen
with gentamicin and oxacillin6.
Recent literature has also focused on the effect of
leukocyte concentration in PRP preparations with re-
gard to antimicrobial activity9,11-13. Anitua et al.11 and
others have proposed that leukocytes play a key role
in the activation of platelets, in regard to their antimi-
crobial activity, by releasing growth factors and cy-
tokines which may serve as platelet activators. How-
ever, the literature is varied when examining the
dose dependent response of leukocyte concentration
in PRP preparations, and further study seems war-
ranted9,11,13.
The purpose of this study is to investigate the an-
tibacterial properties of two different platelet concen-
tration methods using common bacteria responsible
for infections in arthroplastic surgery: Staphylococcus
aureus (S. aureus), Staphylococcus epidermidis (S.
epi), Propionibacterium acnes (P. acnes) and methi-
cillin-resistant Staphylococcus aureus (MRSA) using
a standard time kill assay. The null-hypotheses are:
(1) there will be no difference in bacterial growth be-
tween two different platelet concentration prepara-
tions [(low platelet PRP (PRP LP)and high platelet
PRP (PRPHP)] and (2) there will be no difference in
bacterial growth in preparations with PRP when com-
pared to bacteria treated with positive controls phos-
phate buffered saline (PBS) or whole blood and an
antibiotic as a negative control: Cefazolin (Ancef®,
GlaxoSmithKline, Research Triangle 46 Park, NC).
Methods
The methods described in this paper were considered
best practice in regards to commonly considered
standards for research protocols. Best efforts were
made to make the following justifiable and appropri-
ate for the procurement of the conclusions stated,
and the results from which they were drawn14.
Experimental Groups
Five different experimental groups were formed in-
cluding two positive controls, one negative control,
PRPLP and PRPHP. These groups were then treated
with standard innoculations of Staphylococcus au-
reus, Staphylococcus epidermidis, Propionibacterium
acnes, and methicillin-resistant Staphylococcus au-
reus (MRSA). This yielded 20 tubes, each containing
a different combination of experimental group to
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species of bacterium. Each of these tubes were then
plated in duplicate at two different dilutions for each
group at five different time points (0,1,4,8 and 24
hours). 
Preparation of PRP
Peripheral blood was drawn from two healthy male
volunteers with an average age of 24±1 years. Exclu-
sion criteria comprised any form of anticoagulant, an-
tibacterial or immunosuppressive therapy within last 6
months, any form of systemic illness and current or
recent history of cancer15. Two different PRP prepa-
rations and a whole blood control were obtained from
each volunteer. For the PRPLP preparation, 50 mL of
blood was drawn into a 60 mL syringe prefilled with 5
mL of acid citrate dextrose (ACD-A, noClot 50, Citra
Pharmaceuticals, Braintree, MA). A 12 mL aliquot of
the anticoagulated blood was transferred to Autolo-
gous Conditioned Plasma (ACP) Double Syringes
(Arthrex Inc., Naples, FL), which were then loaded in-
to a centrifuge and spun for 5 minutes at 1500 rpm.
This yielded increased platelet concentration with a
low concentration of white blood cells (PRPLP).
The PRPHP preparation utilized the GPS III Platelet
Concentrate System (Biomet Biologics, Warsaw, IN).
As before, 50 mL of blood was drawn into a 60 mL
syringe prefilled with 5 mL of ACD-A. 27 mL aliquot of
anticoagulated blood was injected into disposable
tubes containing buoy shelves to separate the blood.
The tubes were centrifuged for 15 minutes at 3200
rpm, yielding high platelet and white blood cell con-
centrations (PRPHP)16.
Each native blood specimen and each PRP prepara-
tion were analyzed by the University of Connecticut’s
blood laboratory. The platelet number, number of red
blood cells, and WBC differentiation was determined
by a complete blood counter (Gen-S System 2 Hema-
tology Analyzer; Coulter Corp, Miami, Florida) 17.
A recent article by DeLong et al. suggests using the
PAW Classification System to help standardize PRP
research18. For the purpose of this study PRPLP re-
ceives a P2-Bβ classification while PRPHP receives a
P3-Aα classification. 
Preparation of Bacterial Cultures
Each bacterial strain was subcultured and incubated
for 16 hours at 37° C, after which colonies were mi-
croscopically analyzed for purity. The initial bacterial
concentration for each preparation was standardized
for all experimental and control tubes using a neph-
elometer. Four mL of the standardized inoculum of
each individual strain was added to each experimen-
tal and control tube along with 1mL of control (either
PBS, whole blood, or cefazolin) or experimental
preparation (PRPLP and PRPHP). S. aureus, S. epi,
and MRSA samples were grown in lysogeny broth
(LB) at an initial concentration of 5.0x105 colony form-
ing units per mL (CFU/mL) in a 5mL volume. P. acnes
was grown in Wilkins-Chalgren broth (WC) with an
initial concentration of 1.0x106 CFU/mL in a 5 mL vol-
ume due to its slower growth rate. The cefazolin con-
centration was set at 4 micrograms per mL, which
has demonstrated to be an effective surgical wound
concentration19.
Time Kill Assay
A time kill assay was performed on these prepara-
tions with time points of 0, 1, 4, 8 and 24 hours20. At
each time point, 100μL was removed from each indi-
vidual reaction tube and serial dilutions were per-
formed to yield dilutions of 1:100, 1:1000 and
1:10,000. 50μL of each dilution was then plated on
trypticase soy agar plates with 5% sheep blood (Bec-
ton Dickinson and Company, Sparks MD) in dupli-
cate. The plates were incubated at 37°C for 48 hours
after which the colony counts were determined. The
plates containing P. acnes were incubated under
anaerobic conditions.
Statistical Analysis
Descriptive statistics to characterize the groups were
reported using mean and standard deviation. The
Kolmogorov-Smirnov test was performed for each
continuous measure to identify non-normal distribu-
tions. Between group comparisons of colony growth
at each time point was assessed with Kruskal-Wallis
rank test. For these tests, a probability (p) value of
0.05 was considered significant. Post hoc compar-
isons were performed with the Wilcoxon rank-sum
test and sign-rank test. Given the small group sizes
(n=4), the lowest possible p value that could be
reached with post hoc non-parametric testing was
0.0625 therefore the threshold for significance with
post hoc testing was 0.1. Groups were condensed to
include both PRP donors in a single treatment group
for analysis to permit evaluation of potential trends
among the different treatment groups as opposed to
variations between PRP donors, which has previously
been established16. All statistical analysis was per-
formed using Stata 12 (StataCorp. 2011. Stata Statis-
tical Software: Release 12. College Station, TX: Stat-
aCorp LP).
Results
PRP Preparations
Native venous blood yielded a mean platelet concen-
tration of 135.6  ± 78.4 x 103/μL and 5.4  ±  1.9 x
103/μL of white blood cells. After centrifugation, the
platelet count of the produced PRPLP was 386 ± 65.5
x 103/μL and 867 ± 234.4 x 103/μL for the PRPHP
(p=0.01). The white blood cell count of the produced
PRPLP was 0.62 ± 0.265 x 103/μL and 11.96 ± 4.74 x
103/μL for the PRPHP (p=0.01).
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Bacterial Growth
Both PRPLP and PRPHP showed a significant decrease
(p<0.05) in bacterial growth at 8 hours for all of the
bacterial samples when compared to whole blood. The
results for each individual bacterium are listed below. 
Staphylococcus epidermidis (Fig. 1):
At 1, 4, 8 and 24 hours, both PRPLP and PRPHP limit-
ed S. epidermidis growth relative to the whole blood
standard (p<0.03). At 4 (p<0.02) and 8 hours
(p<0.01), PRPHP was found to significantly limit bacte-
ria relative to PBS. The most significant difference be-
tween PRPHP and PRPLP was at 8 hours (p<0.01). No
significance in bacterial growth was found at any time
point between cefazolin and the PRP preparations.
Staphylococcus aureus (Fig. 2):
At 1, 4, and 8 hours, PRPLP limited S. aureus growth
relative to whole blood (p<0.02). At 1, 4, 8 and 24
hours PRPHP limited S. aureus growth compared to
whole blood (p<0.03). The largest effect of PRPLP
was seen at 8 hours with a 3500% reduction in bacte-
rial growth when compared to whole blood (2.00 x105
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CFU/mL for PRPLP vs 7.05 x106 CFU/mL for the
blood control). PRPLP and PRPHP were found to sig-
nificantly limit bacterial growth relative to PBS at 4
and 8 hours (p<0.01). There was no significant differ-
ence in bacterial growth between cefazolin and the
PRP preparations at any time point.
Propionibacterium acnes (Fig. 3):
At 4, 8, and 24 hours, both PRPLP and PRPHP were
found to limit P. acnes growth relative to whole blood
(p<0.03). At 8 hours, PRPHP was found to limit bacte-
rial growth better than PRPLP (p<0.05). At 24 hours
cefazolin appeared to limit bacterial growth relative to
both PRP preparations, however significance at an
alpha value of 0.05 was not found.
Methicillin Resistant Staphylococcus aureus (MRSA)
(Fig. 4):
At 8 and 24 hours, both PRPLP and PRPHP were found
to limit MRSA growth relative to whole blood (p<0.05).
At 1 and 4 hours, statistical significance was seen be-
tween PRPLP and PRPHP (p<0.03). However, at 24
hours, no statistically significant difference was ob-
served between either PRPLP or PRPHP and cefazolin.
Figure 1. Staphylococcus epider-
midis growth in experimental
groups as measured by colony
count; CFU: Colony forming units.
Legend: PRPLP = platelet rich plasma-low
platelets; PRPHP = platelet rich plasma-
high platelets; PBS = phosphate buffered
saline.
Figure 2. Staphylococcus aureus
growth in experimental groups as
measured by colony count. CFU:
Colony forming units.
Legend: PRPLP = platelet rich plasma-low
platelets; PRPHP = platelet rich plasma-
high platelets; PBS = phosphate buffered
saline.
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Discussion
This study was designed to evaluate two PRP prepara-
tions with regard to antimicrobial activity against S. au-
reus, S. epidermidis, P. acnes, and MRSA. Two com-
mercially available preparations of PRP were used in
this study in an effort to compare low platelet and WBC
concentration to high platelet and WBC concentration. 
The observed anti-bacterial properties of PRP are
consistent with past in vitro studies of S. aureus and
S. epi 4-9. Little evidence exists documenting PRP’s
inhibitory effect on P. acnes and MRSA. Although a
statistically significant effect was found with each
bacteria, the effect of PRPLP and PRPHP on P. acnes
and MRSA was minimal and may not be clinically sig-
nificant. This decreased effect may be explained by
the characteristics of the bacteria studied: P. acnes is
a gram positive anaerobic rod bacteria and MRSA dif-
fers from S. aureus in its altered Penicillin Binding
Protein (PBP). Likewise, the decreased effect of cefa-
zolin is also explained by the microbiology of these
bacterium. Furthermore, the pharmacokinetic and
pharmacodynamic properties of PRP and other an-
tibiotics may prove a more meaningful prediction of in
vivo efficacy than the strength of the agent in vitro 21.
PRP’s maximum inhibition was consistently seen
around 8 hours with inhibitory effects diminishing af-
ter 24 hours. A clinical effect could manifest in the
first few hours following surgery – a crucial time to
counteract any intra-operative bacterial exposure.
Knobben et al. found intra-operative contamination in
as many as 30% of operations22. Likewise, Davis et
al. showed that the vast majority of contaminated op-
erating room equipment was positive for coagulase
negative staphylococci23, an organism that PRP suc-
cessfully inhibited.
In this study, whole blood was chosen as a physiolog-
ically relevant positive control. Hemarthrosis and
blood clots frequently form in the joint following a sur-
gical procedure. Thus, the potential antibacterial
properties of PRP compared to whole blood are clini-
cally relevant. 
Significance between the two PRP preparations was
found at select time points, as seen with S. epidermidis
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Figure 3. Propionibacterium acnes
growth in experimental groups as
measured by colony count. CFU:
Colony forming units.
Legend: PRPLP = platelet rich plasma-low
platelets; PRPHP = platelet rich plasma-
high platelets; PBS = phosphate buffered
saline.
Figure 4. Methicillin Resistant
Staphylococcus aureus growth in
experimental groups as measured
by colony count. CFU: Colony
forming units.
Legend: PRPLP = platelet rich plasma-low
platelets; PRPHP = platelet rich plasma-
high platelets; PBS = phosphate buffered
saline.
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and P. acnes at 8 hours and MRSA at 1 and 4 hours.
In each of these circumstances, PRPHP showed a sig-
nificant decrease over PRPLP. However, at 24 hours
there were no observed statistically significant differ-
ences between the two preparations. 
The platelet concentrations found in PRPLP and
PRPHP were significantly different. This is consistent
with past publications that have demonstrated a sta-
tistically significant difference in platelet counts be-
tween similar PRPLP and PRPHP systems16. Likewise,
these same studies have documented a wide intra-in-
dividual variation in platelets, white blood cells, and
growth factors16.
In 2002, Tang et al. identified seven thrombin-re-
leasable antimicrobial peptides from human platelets:
platelet factor 4 (PF-4), RANTES, connective tissue
activating peptide 3 (CTAP-3), platelet basic protein,
thymosin β-4 (Tβ-4), fibrinopeptide B (FP-B) and fib-
rinopeptide A (FP-A). All except FP-B and FP-A could
also be purified from acid extracts of nonstimulated
platelets. When testing these peptides against E. coli,
S. aureus, Candida albicans and Cryptococcus neo-
formans, antimicrobial activities were found to be
dose dependent. Tang et al.’s findings are consistent
with the dose dependent relationship found in this
study against S. epi, P. acnes and MRSA10.
The role leukocytes play in antimicrobial properties of
PRP concentrations remains a debated topic15. Con-
flicting data has shown both a dose independent and
dose dependent response of antimicrobial activity to
increasing leukocyte concentration in PRP prepara-
tions15. In fact, leukocyte presence in PRP has been
proposed as an additional source of growth factors,
antimicrobial cytokines, and myeloperoxidase activi-
ty24. However, Moorjen et al.9 found no correlation
between myeloperoxidase activity and bactericidal
properties of PRP preparations against staphylococ-
cus aureus. In addition, no difference in antibacterial
activity was seen between PRP preparations with
high-leukocyte concentration, and no leukocytes9.
This study was not designed to differentiate the anti-
microbial activity of platelets relative to leukocytes.
However, our results suggest that in the commercial
setting, PRP preparations with low leukocyte concen-
tration (PRPLP) may produce equal antibacterial ef-
fects relative to preparations which produce higher
leukocyte counts (PRPHP). 
Limitations
There are several limitations of this study. First, the in
vitro behavior of bacterial plates may not mimic the in
vivo environment surrounding the joint. Second, the
clinical benefits are variable and unable to be corre-
lated to a fixed reduction in bacterial number. The ap-
propriate concentration of PRP remains to be further
explored and could have a substantial effect on
PRP’s antibacterial properties. The final limitation
was due to the methods requiring a cumbersome
number of plate assays that were performed to evalu-
ate four bacterial strains, including two experimental
PRP groups, two positive controls, and one negative
control, with additional technical replicates (n=4) with-
in groups. Therefore, the study was only able to use
PRP preparations from two individuals, yielding only
two biological replicates. Therefore, this study cannot
exclude the possibility of inter-donor variability. 
A power analysis was not performed on this in vitro
study. Since we are unable to quantify how an in vitro
reduction in bacterial colonies correlates to a clinical ef-
fect, we did not feel that a power analysis would be jus-
tified. Rather, the goal of this study was to determine
trends amongst the PRP donors as evident by our sta-
tistical analysis which pooled all donors together. 
Conclusion
PRP, regardless of preparation, has shown in vitro
bacteriostatic properties against Staphylococcus au-
reus (S. aureus), Staphylococcus epidermidis (S.
epi ), Propionibacterium acnes (P. acnes) and methi-
cillin-resistant Staphylococcus aureus (MRSA). The
application of PRPLP and PRPHP showed a significant
decrease in bacterial growth after 8 hours for S. au-
reus, S. epi, MRSA and P. acnes compared to the
whole blood control group. S. epi, MRSA, and P. ac-
nes also showed a significant decrease in bacterial
growth after 24 hours. Despite differences in platelet
concentration and WBC concentration, no difference
in antibacterial activity was seen between the two
preparations. 
The University of Connecticut Health Center/New
England Musculoskeletal Institute has received direct
funding and material support for this study from
Arthrex Inc. (Naples, FL). The company had no influ-
ence on study design, data collection or interpretation
of the results or the final manuscript.
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